A 5-year-old girl with Ph-positive chronic myelogenous leukemia, who underwent umbilical cord blood transplantation, developed two episodes of electrical status epilepticus while receiving tacrolimus (FK506) then cyclosporin A (CsA), as treatment against graft-versushost disease. MRI including diffusion weighted MR imaging of the brain revealed abnormalities in the hippocampus and posterior white matter following FK506 and CsA treatment, respectively. While posterior white matter injury has been described with both FK506 and CsA, no previous report describes hippocampal injury from either drug. The MRI changes in the hippocampus in our case suggest possible increased susceptibility to hippocampal injury with FK506.
philin; DWI FK506 (tacrolimus) and cyclosporin A (CsA) are immunosuppressive agents used in bone marrow and organ transplantation treatment. Both agents share a similar mechanism of immunosuppressive action, and are known to show similar neurotoxicity.
1,2 A case with independent episodes of FK506-and CsA-associated neurotoxicity is discussed, with different MRI findings including diffusion weighted MR imaging (DWI).
Case report
A 5-year-old girl was diagnosed with Ph-positive chronic myelogenous leukemia during a blast crisis. She achieved complete hematological remission following continuous intravenous infusion of Ara-C at 20 mg/m 2 /day for 3 weeks. Following pretreatment with Ara-C of 24 g/m 2 and total body irradiation of 12 Gy, she underwent umbilical cord blood transplantation from a 5/6 major HLA-antigen matched unrelated donor, 2 months after achieving remission. She received CsA (3 mg/kg/day in two divided doses) and short-term methotrexate (15 mg/m 2 Â 1, 10 mg/ m 2 Â 3) for prophylaxis against graft-versus-host disease (GVHD). The blood concentration of CsA did not reach the effective level, although the dose of CSA was increased to 6 mg/kg/day. On day 20 post transplantation, she developed a skin rash, and was diagnosed with stage II acute GVHD of the skin. Prednisolone (PSL) (2 mg/kg/ day) was added, and a continuous infusion of FK506 (0.025 mg/kg/day) was substituted for CsA.
On day 26, she developed severe intermittent headache and hypertension (160/110 mmHg). She was afebrile, and had no other symptoms. She had temporary relief with a single dose of sublingual nifedipine (3 mg/dose), and the blood pressure improved to 120/81 mmHg. She developed dizziness and drowsiness, and subsequently became unconscious with worsening hypertension (162 mmHg) and tachycardia (156/min). Her pupils became dilated with sluggish light reflexes. Platelets were 9.0 Â 10 9 /l despite transfusion performed on the previous day. Her hemoglobin level was 10.8 g/dl, and white blood cell count was 0.4 Â 10 9 /l. No fragmentation of red blood cells was seen on a peripheral blood smear. Blood chemistry values including electrolytes and liver transaminases were within normal limits. Head CT was unremarkable. FK506 was discontinued due to suspected FK506-related neurotoxicity (serum FK506 level: 14.6 ng/ml). She remained unconscious, and was intubated for respiratory distress with an O 2 saturation of 77 percent despite receiving O 2 via facemask. She jerked intermittently and irregularly while ventilated. An electroencephalogram (EEG), 2 h into the episode, showed rhythmic generalized spike-and-wave complexes, consistent with electrical status epilepticus ( Figure 1a) . The rhythmic discharges disappeared after a dose of intravenous midazolam (0.1 mg/kg) (Figure 1b) . The status epilepticus and resultant hypoxic state may have lasted for as long as 2 h, from the onset of the actual jerking which lasted for 30 min. She regained consciousness within 5 h after the electrographic seizure had stopped. Her blood pressure decreased to 120/85 mmHg. MRI of the brain including DWI was obtained 4 days after the seizure. Highintensity lesions were seen bilaterally with DWI in the hippocampi and parahippocampal gyri (Figure 2a ). High intensity bilateral lesions in the hippocampi were also seen on T2-weighted images (T2WI) (Figure 2b ), but were less obvious compared to DWI. T1-weighted images (T1WI) and fluid-attenuated inversion recovery (FLAIR) images were unremarkable. Follow-up MRI, 7 days later, also showed high-intensity lesions on DWI in the same areas, not detected by other sequences. She had difficulty with short-term memory and was unable to remember objects, for 10 days following the seizure.
She progressed to stage III acute GVHD of the skin on day 40 while being treated with PSL (2 mg/kg/day) alone. She received high-dose methylprednisolone (30 mg/kg/day) for 2 days and antithymoglobulin (ATG) (1.8 mg/kg/day) for 4 days. Both therapies were only transiently effective, and she developed a generalized exfoliative rash with deteriorating performance status (grade IV acute GVHD). To improve control of GVHD, a continuous infusion of CsA (3 mg/kg/day) was started on day 53, and PSL was increased to 4 mg/kg/day on day 56. On day 63, she suffered another episode of abrupt alteration in consciousness with hypertension (160 mmHg) and tachycardia (150/ min). She had eye deviation and head jerking to the right, consistent with right-sided motor seizure activity. The seizure lasted 20 min, and stopped after a dose of intravenous midazolam (0.1 mg/kg), followed by a single dose of intravenous phenytoin (10 mg/kg). The seizure was suspected to be CsA-related, and CsA was discontinued (serum CsA level: 196 ng/ml). Blood chemistry values were within normal limits except for elevated liver enzymes (GOT, 462 IU/l; GPT, 696 IU/l; LDH, 645 IU/l). No red cell fragmentation was seen on the peripheral blood smear. She had no obvious additional neurological deficit after she recovered from the seizure. CsA was restarted (3 mg/kg/ day) on the following day for acute GVHD. An MRI of the brain, 2 days after the seizure while on CsA, showed high-intensity lesions in the left occipital lobe, on DWI (Figure 3a) , T2WI (Figure 3b) , and FLAIR images. The previous hippocampal abnormalities appeared as lowintensity lesions on DWI. Follow-up MRI on day 109 showed diffuse atrophy, especially in the hippocampi, bilaterally. No high-intensity lesions were seen on DWI, while she was still receiving CsA treatment for GVHD. She had no further episodes of seizures or headaches. Up to 22 months post transplantation, she appears to have no obvious difficulty with her short-term memory although she continues to receive PSL (0.1 mg/kg/day) and CsA (1.6 mg/kg/day) for chronic GVHD of lung, liver, and skin.
Discussion
Many cases involving neurological and psychiatric complications have been reported in association with immunosuppressants FK506 and/or CsA. Severe neurological complications include psychoses, hallucinations, blindness, seizures, cerebellar ataxia, motor weakness, and leuko- It is uncertain to what extent the possible risk factors contribute independently to the process. The patient was receiving not only the above-mentioned drugs but also others, including acyclovir, ganciclovir, fluconazole, arbekacin sulfate, and panipenem/betamipron; effects of these drugs may have complicated the course. Hypertension, hypoxic-ischemic injury, and prolonged status epilepticus may be particularly critical to mechanisms of brain injury in our case. Hypertension has been noted in patients with CsA and FK506, but also can be seen with high doses of PSL. [1] [2] [3] The leukoencephalopathy seen with CsA and FK506 is observed predominantly in the occipital areas, as in hypertensive encephalopathy with vasogenic edema, 4 but it may or may not be accompanied by hypertension. The proposed mechanism of such leukoencephalopathy is endothelial injury of blood vessels from CsA and FK506. 5 The MRI changes seen with CsA in our case appear to follow the pattern of the previously reported leukoencephalopathy. However, the limbic injury, predominantly in hippocampal and parahippocampal regions seen with FK506 in our case, differs strikingly from the pattern cited above, which suggests possible increased susceptibility of the hippocampus to injury from FK506.
Hypoxic-ischemic injury is known to be a cause of neuronal injury in the limbic areas. The patient had respiratory distress and required mechanical ventilation for respiratory support, which may have caused hypoxicischemic brain injury, and contributed to the hippocampal injury. Multiple experimental studies of status epilepticus have shown injury with neuronal loss and gliosis in the hippocampus. The bilateral hippocampal injury seen with FK506 in our case is consistent with the findings in experimental models of prolonged status epilepticus. However, given the extensive and selective injury in the hippocampal and parahippocampal regions seen in our case, additional vulnerability of these regions should be considered with FK506.
Regarding the molecular mechanisms of action, FK506 and CsA bind to immunophilin molecules, FK506 binding protein (FKBP) and cyclophilin, respectively, to form active heterodimers. These heterodimers inhibit phosphatase activity of calcineurin (CaN), which leads to the immunosuppressive effects of FK506 and CsA. 6 FKBP and cyclophilin are colocalized with CaN in most regions of the brain, while CaN is highly enriched in the dentate gyrus of the hippocampus. 7 The distribution of immunophilins in the brain and CaN in the hippocampus suggests selective susceptibility of the hippocampus to injury from FK506 and CsA. However, in our case, hippocampal lesions developed with FK506 but not with CsA. The FK506-FKBP heterodimer has been reported to have a greater than 20-fold affinity to CaN, compared to the CsAcyclophilin heterodimer. 8 The higher affinity for FK506 to CaN may have contributed to the selective injury in the hippocampal regions from FK506 but not CsA.
Regarding the neuroimaging findings, whereas occipital white matter lesions from CsA and FK506 have been well documented, 1,2 no report describes hippocampal injury from these agents. As illustrated in our case, the acute hippocampal injury is better visualized on DWI, compared to the conventional MRI sequences, and may have been underdiagnosed in the past. Bilateral hippocampal injury is of much clinical significance, because of the risk of subsequent epilepsy and cognitive deficits. Further studies may be necessary to confirm the findings of limbic injury including injury to the hippocampus, and to investigate the long-term consequences.
In conclusion, no previous report describes hippocampal injury from FK506. The findings of limbic injury including the hippocampus in the present study suggest a possible increased susceptibility of the hippocampal formation to injury from FK506.
